Xilio Therapeutics price to book ratio XLO

Market value divided by the book value of the company's net assets, since 2022.

Today, Oct 23, 2026: 0.6×
5-year median: 0.9×
Against its 5-year history: 25th; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.3× to 6.0×
Peer median: 1.5×

Xilio Therapeutics' price to book ratio is 0.6× as of Oct 23, 2026.

That is below its 5-year median of 0.9×, lower than on 75% of days in the last 5 years.

Over that time it ranged from 0.3× in Dec 2023 to 6.0× in Oct 2025.

The median for 4 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.6×	0.6×	1.4×
2025	5.9×	1.4×	6.0×
2024	2.0×	0.3×	2.7×
2023	0.3×	0.3×	1.2×
2022	0.6×	0.3×	1.3×

Against its peers

Companies in Drug Manufacturers - General nearest Xilio Therapeutics' size, closest first, today.

Company	Price to book ratio
XLOXilio Therapeutics	0.6×
ATNMActinium Pharmaceuticals	1.6×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
NATRNatures Sunshine Products	1.3×
Peer median	1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Xilio Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.